von Willebrand disease: Clinical and laboratory lessons learned from the large von Willebrand disease studies
Authors:
Open Access
- 8 February 2012
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 87 (S1) , S4-S11
Abstract
During the past 25 years, our knowledge concerning the pathogenesis, diagnostic strategies, and treatment of von Willebrand disease (VWD) has increased significantly. Following the immunological differentiation of factor VIII (FVIII) and von Willebrand factor (VWF) in the 1970s and the cloning of the FVIII and VWF genes in the mid‐1980s, substantial progress has been made in our understanding of this, the most common inherited bleeding disorder. We now recognize that VWD represents a range of genetic diseases all with the clinical endpoint of increased mucocutaneous bleeding. The molecular pathology of Type 2 and 3 VWD is now comprehensively documented and involves rare sequence variants at the VWF locus. In contrast, the genetic causation of Type 1 disease remains incompletely defined and in many cases appears to involve genetic determinants in addition to or instead of VWF. The diagnostic triad of a personal history of excessive mucocutaneous bleeding, laboratory tests for VWF that are consistent with VWD, and a family history of the condition remain the keystone to VWD identification. In the laboratory, measurement of VWF antigen and function continue to be the most important diagnostic studies, and while our understanding of the molecular genetic pathology of VWD has advanced considerably in the past decade, genetic testing as a component of diagnosis is limited to certain distinct subtypes of the disorder. Treatment of VWD has been relatively unchanged for the past decade and continues to involve either stimulation of the release of intrinsic VWF with desmopressin or the infusion of VWF concentrates. Am. J. Hematol. 2012.Keywords
This publication has 92 references indexed in Scilit:
- VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American populationBlood, 2012
- Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formationHaematologica, 2011
- Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohortBlood, 2011
- Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse modelsBlood, 2011
- Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand diseaseBlood, 2010
- Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaireJournal of Thrombosis and Haemostasis, 2010
- Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand FactorCirculation, 2010
- Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)Blood, 2008
- Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survivalBlood, 2006
- Prevalence of von Willebrand disease in children: A multiethnic studyThe Journal of Pediatrics, 1993